bup xr (Camurus Inc)
86
Structured Review
Camurus Inc
bup xr
Bup Xr, supplied by Camurus Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bup/bup+xr/pm41483733-52-46-50
Average 86 stars, based on 1 article reviews
Bup Xr, supplied by Camurus Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bup/bup+xr/pm41483733-52-46-50
Average 86 stars, based on 1 article reviews
bup xr - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
other:Article Title: Selected Abstracts from Pharmacology 2022. Article Snippet: Selected Abstracts from Pharmacology 2022 Posters, Tuesday 13th September Poster presentations—Molecular and cellular P025 | NanoBiT/BRET assessment of eGFP-WNT-3A binding to FZD7 in SW480 cells under endogenous promotion Pawel Kozielewicz; Lukas Grätz; Joanna Sajkowska-Kozielewicz; Stefanie Moser; Gary Davidson; Gunnar Schulte Karolinska Institutet; Karlsruhe Institute of Technology Introduction/Background & aims: The 10 mammalian Frizzleds (FZD1–10) are G protein-coupled receptors (GPCRs) which, together with Smoothened (SMO), constitute the class F of GPCRs.. The 19 WNT lipoglycoproteins are the ligands of FZDs, and they interact with the extracellular cysteine-rich domain (CRD) of the receptor.. Our previous analysis of all 10 human FZD paralogues revealed differences in the profile of eGFP-WNT-3A binding [1]. Article Title: Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. Article Snippet: Article Title: 96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial. Article Snippet: NL has received reimbursement for participation in Advisory Boards for Mundipharma, Indivior and Chiesi Pharmaceuticals; he received funding from Article Title: Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. Article Snippet: NL has received reimursement for participation in Advisory Boards for Mundipharma, Inivior and Chiesi Pharmaceuticals; he received funding from Camurus or a company-sponsored trial of BUP-XR. Article Title: Provider costs of treating opioid dependence with extended‐release buprenorphine in Australia Article Snippet: Disruption:Article Title: Initiation, retention, and discontinuation of extended-release buprenorphine (BUP-XR) for opioid dependence: A single-arm multi-site trial in Ukraine. Article Snippet: Background: Opioid agonist therapy (OAT) is an essential tool for reducing illicit opioid use and mortality.. Extended-release formulations of buprenorphine (BUP-XR) show promise in improving adherence and increasing treatment uptake, but real-world studies show mixed results.. Previous studies of BUP-XR were conducted in highincome countries. |